Biomerica Reports Second Quarter Fiscal 2025 Financial Results
1. Biomerica's revenue increased 5% year-over-year to $1.64 million. 2. Launch of inFoods® IBS test allows direct-to-consumer purchasing. 3. Three key patents enhance Biomerica's market opportunities for digestive diseases. 4. Significant cost savings achieved, reducing net loss by 37% to $950,000. 5. Gross margins improved from 21% to 27%, reflecting a favorable sales mix.